| 03/12/21 | HCM | 07:00:04 | 3 Dec 2021 | | HCM | Updated NRDL to include ELUNATE and SULANDA | Hutchmed (China) Limited | RNS |
| 30/11/21 | HCM | 08:30:05 | 30 Nov 2021 | | HCM | Total Voting Rights | Hutchmed (China) Limited | RNS |
| 24/11/21 | HCM | 07:00:04 | 24 Nov 2021 | | HCM | HUTCHMED and AZ Initiate SACHI Phase 3 Trial | Hutchmed (China) Limited | RNS |
| 08/11/21 | HCM | 07:00:09 | 8 Nov 2021 | | HCM | HUTCHMED to Present Clinical Data at ASH | Hutchmed (China) Limited | RNS |
| 01/11/21 | HCM | 07:00:14 | 1 Nov 2021 | | HCM | HUTCHMED and AZ Initiate SAMETA Global P3 Trial | Hutchmed (China) Limited | RNS |
| 29/10/21 | HCM | 09:30:02 | 29 Oct 2021 | | HCM | Total Voting Rights | Hutchmed (China) Limited | RNS |
| 28/10/21 | HCM | 07:00:04 | 28 Oct 2021 | | HCM | HUTCHMED Initiates Phase III Trial of HMPL-523 | Hutchmed (China) Limited | RNS |
| 20/10/21 | HCM | 09:30:03 | 20 Oct 2021 | | HCM | Grant of Awards under Long Term Incentive Plan | Hutchmed (China) Limited | RNS |
| 30/09/21 | HCM | 09:30:07 | 30 Sept 2021 | | HCM | Total Voting Rights | Hutchmed (China) Limited | RNS |
| 29/09/21 | HCM | 07:00:10 | 29 Sept 2021 | | HCM | Closure of Non-Core OTC Joint Venture Divestment | Hutchmed (China) Limited | RNS |
| 29/09/21 | HCM | 07:00:10 | 29 Sept 2021 | | HCM | HUTCHMED Highlights Presentations at CSCO 2021 | Hutchmed (China) Limited | RNS |
| 21/09/21 | HCM | 07:00:10 | 21 Sept 2021 | | HCM | HUTCHMED Initiates Phase III Trial SURTORI-01 | Hutchmed (China) Limited | RNS |
| 20/09/21 | HCM | 07:00:09 | 20 Sept 2021 | | HCM | Japan Bridging Study For Surufatinib Initiated | Hutchmed (China) Limited | RNS |
| 13/09/21 | HCM | 07:00:08 | 13 Sept 2021 | | HCM | Breakthrough Therapy Designation for Amdizalisib | Hutchmed (China) Limited | RNS |
| 08/09/21 | HCM | 11:30:00 | 8 Sept 2021 | | HCM | HUTCHMED and AZ Initiate Phase III Trial in China | Hutchmed (China) Limited | RNS |
| 07/09/21 | HCM | 09:30:08 | 7 Sept 2021 | | HCM | HUTCHMED to Present Clinical Data at ESMO | Hutchmed (China) Limited | RNS |
| 06/09/21 | HCM | 07:00:08 | 6 Sept 2021 | | HCM | HUTCHMED Shares Included in Stock Connect Programs | Hutchmed (China) Limited | RNS |
| 02/09/21 | HCM | 12:45:06 | 2 Sept 2021 | | HCM | Grant of Share Options, and Awards under LTIP | Hutchmed (China) Limited | RNS |
| 31/08/21 | HCM | 09:30:01 | 31 Aug 2021 | | HCM | Total Voting Rights | Hutchmed (China) Limited | RNS |
| 26/08/21 | HCM | 07:00:03 | 26 Aug 2021 | | HCM | Phase Ib/II Trial of Fruquintinib & Tislelizumab | Hutchmed (China) Limited | RNS |
| 23/08/21 | HCM | 07:00:06 | 23 Aug 2021 | | HCM | HUTCHMED Selected for Certain Hang Seng Indexes | Hutchmed (China) Limited | RNS |
| 17/08/21 | HCM | 09:30:03 | 17 Aug 2021 | | HCM | ELECTRONIC COMMUNICATION OF CORPORATE INFORMATION | Hutchmed (China) Limited | RNS |
| 09/08/21 | | 07:00:07 | 9 Aug 2021 | | | HUTCHMED & Epizyme Announce TAZVERIK Collaboration | Hutchmed (China) Limited | RNS |
| 30/07/21 | | 09:30:06 | 30 Jul 2021 | | | Total Voting Rights | Hutchmed (China) Limited | RNS |
| 28/07/21 | | 12:00:01 | 28 Jul 2021 | | | Interim Results and Business Updates | Hutchmed (China) Limited | RNS |
| 28/07/21 | | 07:00:09 | 28 Jul 2021 | | | Phase II Trial of ORPATHYS Initiated | Hutchmed (China) Limited | RNS |
| 23/07/21 | | 12:01:35 | 23 Jul 2021 | | | Stabilizing Actions & End of Stabilization Period | Hutchmed (China) Limited | RNS |
| 16/07/21 | | 10:50:00 | 16 Jul 2021 | | | Holding(s) in Company | Hutchmed (China) Limited | RNS |
| 16/07/21 | | 07:00:03 | 16 Jul 2021 | | | Surufatinib MAA Submitted and Validated by the EMA | Hutchmed (China) Limited | RNS |
| 14/07/21 | | 09:35:01 | 14 Jul 2021 | | | Holding(s) in Company | Hutchmed (China) Limited | RNS |
| 13/07/21 | | 07:00:05 | 13 Jul 2021 | | | First Commercial Sale of ORPATHYS® in China | Hutchmed (China) Limited | RNS |
| 12/07/21 | | 14:35:02 | 12 Jul 2021 | | | Full Exercise of the Over-allotment Option | Hutchmed (China) Limited | RNS |
| 06/07/21 | | 09:30:01 | 6 Jul 2021 | | | HUTCHMED Initiates Phase I Trials of HMPL-295 | Hutchmed (China) Limited | RNS |
| 02/07/21 | | 11:15:01 | 2 Jul 2021 | | | Holding(s) in Company | Hutchmed (China) Limited | RNS |
| 02/07/21 | | 09:30:01 | 2 Jul 2021 | | | Notice of Results | Hutchmed (China) Limited | RNS |
| 01/07/21 | | 11:00:01 | 1 Jul 2021 | | | US FDA Accepts NDA Filing for Surufatinib | Hutchmed (China) Limited | RNS |
| 30/06/21 | | 10:02:01 | 30 Jun 2021 | | | Holdings in Company | Hutchmed (China) Limited | RNS |
| 30/06/21 | | 10:01:01 | 30 Jun 2021 | | | Total Voting Rights | Hutchmed (China) Limited | RNS |
| 30/06/21 | | 10:00:01 | 30 Jun 2021 | | | Closing of Global Offering and Hong Kong Listing | Hutchmed (China) Limited | RNS |
| 29/06/21 | | 07:00:04 | 29 Jun 2021 | | | Blocklisting Six Monthly Return | Hutchmed (China) Limited | RNS |
| 23/06/21 | | 15:21:52 | 23 Jun 2021 | | | HUTCHMED Announces Pricing of Global Offering | Hutchmed (China) Limited | RNS |
| 22/06/21 | | 18:22:05 | 22 Jun 2021 | | | Savolitinib approved in China for lung cancer | Hutchmed (China) Limited | RNS |
| 18/06/21 | | 16:05:04 | 18 Jun 2021 | | | HUTCHMED Announces NMPA Approval of Surufatinib | Hutchmed (China) Limited | RNS |
| 18/06/21 | | 07:01:01 | 18 Jun 2021 | | | HUTCHMED Launches Hong Kong IPO | Hutchmed (China) Limited | RNS |
| 18/06/21 | | 07:00:04 | 18 Jun 2021 | | | Disclosure Update | Hutchmed (China) Limited | RNS |
| 20/05/21 | | 07:00:11 | 20 May 2021 | | | Clinical Data to be Presented at ASCO21 | Hutchmed (China) Limited | RNS |
| 17/05/21 | | 07:00:15 | 17 May 2021 | | | HUTCHMED to Host Company Update | Hutchmed (China) Limited | RNS |
| 07/05/21 | | 12:00:01 | 7 May 2021 | | | HUTCHMED to Attend Upcoming Investor Conferences | Hutchmed (China) Limited | RNS |
